I own stock in TORC, and everything I say shouldn't be taken at face value. That being said, I do think realistically, TORC had a really negative run after its IPO, but it is in the process of doing clinical trials for really advanced aging diseases such as Parkinson's. The fact that it is a biopharmaceutical stock makes the price crash not too alarming giving the...